Jazz Pharmaceuticals’ (JAZZ) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $210.00 price objective on the specialty pharmaceutical company’s stock. JAZZ has been the subject of a number of other research reports. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from […]
Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $210.00 price objective on the specialty pharmaceutical company’s stock. JAZZ has been the subject of a number of other research reports. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from […]
